Abstract:OBJECTIVES: To screen and identify ideal leading compounds from a drug library (ZINC15 database) with potential inhibition of aminopeptidase N(CD13) to contribute to medication design and development.RESULTS: Two novel natural compounds, ZINC000000895551 and ZINC000014820583, from the ZINC15 database were found to have a higher binding affinity and more favorable interaction energy binding with CD13 with less rodent carcinogenicity, Ames mutagenicity, and non-inhibition with cytochrome P-450 2D6. Molecular dynamics simulation analysis suggested that the 2 complexes, ZINC000000895551-CD13 and ZINC000014820583-CD13, have favorable potential energy, and exist stably in the natural circumstances.CONCLUSION: This study discovered that ZINC000000895551 and ZINC000014820583 were ideal leading compounds to be inhibitions targeting to CD13. These compounds were selected as safe drug candidates as CD13 target medication design and improvement.MATERIALS AND METHOD: Potential inhibitors of CD13 were identified using a series of computer-aided structural and chemical virtual screening techniques. Structure-based virtual screening was carried out to calculate LibDock scores, followed by analyzing their absorption, distribution, metabolism, and excretion and toxicity predictions. Molecule docking was employed to reveal binding affinity between the selected compounds and CD13. Molecular dynamics simulation was applied to evaluate stability of the ligand-CD13 complex under natural environment.

Design, Synthesis and Primary Activity Assay of Bi- or Tri-Peptide Analogues with the Scaffold L-Arginine As Amino-Peptidase N/CD13 Inhibitors

Design, Synthesis, and QSAR Studies of Novel Lysine Derives As Amino-Peptidase N/CD13 Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Structure-Based Design Of Tripeptide Derivatives Of α-Aminoalkylphosphonate Esters For Prostate-Specific Antigen Inhibition

Design, Synthesis, and Primary Activity Evaluation of Pyrrolidine Derivatives As Matrix Metalloproteinase Inhibitors.

Design, Synthesis and Biological Evaluation of New Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design, Synthesis and Preliminary Evaluation of New Cinnamoyl Pyrrolidine Derivatives As Potent Gelatinase Inhibitors

Exploration of Novel Macrocyclic Dipeptide N-benzyl Amides As Proteasome Inhibitors.

Protein Catabolic Enzymes Inhibitory Activities of Pyrrolidine Derivatives

Novel Leucine Ureido Derivatives As Aminopeptidase N Inhibitors. Design, Synthesis and Activity Evaluation.

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Sulfonamide Derivatives Containing Dihydropyrazole Moieties Selectively and Potently Inhibit Mmp-2/Mmp-9: Design, Synthesis, Inhibitory Activity and 3D-Qsar Analysis

Computational study of novel natural inhibitors targeting aminopeptidase N(CD13)

Novel CADD-based Peptidyl Vinyl Ester Derivatives As Potential Proteasome Inhibitors

Design, synthesis, anti-trypsin and anti-inflammatory evaluation of new guanidinobenzoic acid ester derivatives

Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions

Identification of Bioactive Peptides from a Laminaria digitata Protein Hydrolysate Using In Silico and In Vitro Methods to Identify Angiotensin-1-Converting Enzyme (ACE-1) Inhibitory Peptides

Design and Evaluation of Four Novel Tripeptides As Potent Angiotensin Converting Enzyme (ACE) Inhibitors with Anti-Hypertension Activity

Rational design, synthesis and pharmacological characterization of novel aminopeptidase A inhibitors

Chemically Synthesized Matrix Metalloproteinase and Angiogenesis-Inhibiting Peptides As Anticancer Agents.